Study of a pill and CAR T-cell therapy for CLL/SLL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a combination of two treatments: a targeted pill (nemtabrutinib) and a special immune cell therapy (lisocabtagene maraleucel, or liso-cel) for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or has not responded to previous treatment. The goal is to see if giving the pill first helps the cell therapy work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of CLL or SLL that has come back or is hard to treat.
- You must have measurable disease, like a lymph node larger than 1.5 cm on a scan or a high number of leukemia cells in your blood or bone marrow.
- You must be able to swallow and keep down pills (a feeding tube into the stomach is not allowed for the pill).
- You must be age 18 or older.
- You must be well enough to get around (ECOG performance status of 0 to 2).
- Your heart, kidney, and liver function must be within study limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (nemtabrutinib and venetoclax) to treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in patients who have never received cancer treatment before. The goal is to see if this combination can shrink the cancer and help patients live longer.
This trial tests a new drug, nemtabrutinib, against two standard treatments for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who haven't had treatment yet. The goal is to see if the new drug works better at controlling the disease.
This trial tests adding a targeted pill (nemtabrutinib) to standard CAR T-cell therapy for people with mantle cell lymphoma that has come back or not responded to treatment. The goal is to see if this combination works better than CAR T alone.
This Phase 3 study tests whether adding nemtabrutinib to venetoclax works better than the usual next treatment approach (venetoclax plus rituximab) in people with relapsed or treatment-resistant CLL/SLL. It may help by improving how well the cancer responds after at least one prior therapy.
This trial tests a combination of two treatments—CAR T-cells (your own immune cells reprogrammed to attack cancer) and lenalidomide (a pill that boosts the immune system)—for people with chronic lymphocytic leukemia (CLL) that has not responded to or returned after at least one prior treatment. It aims to see if this combination is safe and works better than either alone.
This trial tests a new investigational drug, BGB-16673, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already tried two types of treatments (BTK and BCL2 inhibitors). The goal is to see if this new drug works better than other available treatments chosen by the doctor.
Hear when a new Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.